PRME - Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences | Benzinga
CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Company will showcase advances in preclinical data across the Prime Editing pipeline and platform at several healthcare industry conferences in October and November 2023.
"We are pleased to share new preclinical research across our programs, including proof-of-concept data from in vivo rodent and large animal studies, which showcase the strength of our science," said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. "Together, we believe the breadth of these data represents significant progress across our portfolio and reinforces the potential of Prime Editing to offer curative genetic therapies for a wide spectrum of diseases."
Presentation information is as follows:
AIChE International Conference on CRISPR Technologies
- Presentation Date: October 19, 2023
- Title: Developing and Optimizing Prime Editors to Treat Repeat Expansion Diseases
- Location: Boston
Advances in Prime Editing technology and updates from several Prime Medicine Repeat Expansion Disease programs.
Stem Cell Clonality and Genome Stability Retreat at ESGCT
- Presentation Date: October 23, 2023
- Title: Prime Editing in Hematopoietic Diseases and Beyond: Efficacy and Safety
- Location: Brussels
Overview of Prime Medicine's comprehensive proprietary approach to off-target analysis, including details of off-target analyses from Prime Medicine's programs.
Oligonucleotide Therapeutics Society (OTS) Annual Meeting
- Presentation Date: October 24, 2023
- Title: Recent Advances in Non-Viral Delivery of Prime Editors Toward the Treatment of Patients with Glycogen Storage Disease Type 1b (GSD1b)
- Location: Barcelona
Advances in Prime Medicine's lipid nanoparticle (LNP) and all-RNA delivery platforms for liver disease.
International Symposium on Retinal Degeneration (RD2023)
- Presentation Date: October 24, 2023
- Title: Prime Editors Efficiently and Precisely Correct Pathological Mutations Causing Rhodopsin Associated Autosomal Dominant Retinitis Pigmentosa (adRP)
- Location: Costa del Sol, Spain
First in vivo proof-of-concept data in adRP, including mutational hotspot Prime Editing, initial safety data for lead Retinitis Pigmentosa program, and highlights from Prime Medicine's modular retinal delivery platform.
European Society of Gene and Cell Therapy (ESGCT)
- Presentation Date: October 27, 2023
- Title: Prime Editing Precisely Corrects Prevalent Pathogenic Mutations Observed in Glycogen ...